Literature DB >> 26516200

Immunogenicity of somatic mutations in human gastrointestinal cancers.

Eric Tran1, Mojgan Ahmadzadeh1, Yong-Chen Lu1, Alena Gros1, Simon Turcotte1, Paul F Robbins1, Jared J Gartner1, Zhili Zheng1, Yong F Li1, Satyajit Ray1, John R Wunderlich1, Robert P Somerville1, Steven A Rosenberg2.   

Abstract

It is unknown whether the human immune system frequently mounts a T cell response against mutations expressed by common epithelial cancers. Using a next-generation sequencing approach combined with high-throughput immunologic screening, we demonstrated that tumor-infiltrating lymphocytes (TILs) from 9 out of 10 patients with metastatic gastrointestinal cancers contained CD4(+) and/or CD8(+) T cells that recognized one to three neo-epitopes derived from somatic mutations expressed by the patient's own tumor. There were no immunogenic epitopes shared between these patients. However, we identified in one patient a human leukocyte antigen-C*08:02-restricted T cell receptor from CD8(+) TILs that targeted the KRAS(G12D) hotspot driver mutation found in many human cancers. Thus, a high frequency of patients with common gastrointestinal cancers harbor immunogenic mutations that can potentially be exploited for the development of highly personalized immunotherapies.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26516200      PMCID: PMC7445892          DOI: 10.1126/science.aad1253

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  26 in total

1.  Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.

Authors:  M K Gjertsen; J Bjorheim; I Saeterdal; J Myklebust; G Gaudernack
Journal:  Int J Cancer       Date:  1997-09-04       Impact factor: 7.396

2.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

Review 3.  KRAS: feeding pancreatic cancer proliferation.

Authors:  Kirsten L Bryant; Joseph D Mancias; Alec C Kimmelman; Channing J Der
Journal:  Trends Biochem Sci       Date:  2014-01-02       Impact factor: 13.807

4.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

Authors:  Andrea Sottoriva; Inmaculada Spiteri; Sara G M Piccirillo; Anestis Touloumis; V Peter Collins; John C Marioni; Christina Curtis; Colin Watts; Simon Tavaré
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-14       Impact factor: 11.205

5.  A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.

Authors:  Boris Linard; Stéphane Bézieau; Houssem Benlalam; Nathalie Labarrière; Yannick Guilloux; Elisabeth Diez; Francine Jotereau
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 7.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

8.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

View more
  311 in total

1.  Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).

Authors:  Despoina Koumantou; Eilon Barnea; Adrian Martin-Esteban; Zachary Maben; Athanasios Papakyriakou; Anastasia Mpakali; Paraskevi Kokkala; Harris Pratsinis; Dimitris Georgiadis; Lawrence J Stern; Arie Admon; Efstratios Stratikos
Journal:  Cancer Immunol Immunother       Date:  2019-06-20       Impact factor: 6.968

2.  Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.

Authors:  Nicolas J Llosa; Brandon Luber; Ada J Tam; Kellie N Smith; Nicholas Siegel; Anas H Awan; Hongni Fan; Teniola Oke; JiaJia Zhang; Jada Domingue; Elizabeth L Engle; Charles A Roberts; Bjarne R Bartlett; Laveet K Aulakh; Elizabeth D Thompson; Janis M Taube; Jennifer N Durham; Cynthia L Sears; Dung T Le; Luis A Diaz; Drew M Pardoll; Hao Wang; Robert A Anders; Franck Housseau
Journal:  Clin Cancer Res       Date:  2019-05-06       Impact factor: 12.531

3.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.

Authors:  Diego Chowell; Luc G T Morris; Claud M Grigg; Jeffrey K Weber; Robert M Samstein; Vladimir Makarov; Fengshen Kuo; Sviatoslav M Kendall; David Requena; Nadeem Riaz; Benjamin Greenbaum; James Carroll; Edward Garon; David M Hyman; Ahmet Zehir; David Solit; Michael Berger; Ruhong Zhou; Naiyer A Rizvi; Timothy A Chan
Journal:  Science       Date:  2017-12-07       Impact factor: 47.728

4.  Cellular therapy against public neoantigens.

Authors:  Paul M Armistead
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

Review 5.  Regulation of CTNNB1 signaling in gastric cancer and stem cells.

Authors:  Shihori Tanabe; Kazuhiko Aoyagi; Hiroshi Yokozaki; Hiroki Sasaki
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

Review 6.  Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.

Authors:  Chung-Han Lee; Roman Yelensky; Karin Jooss; Timothy A Chan
Journal:  Trends Immunol       Date:  2018-05-08       Impact factor: 16.687

7.  Development of an epitope panel for consistent identification of antigen-specific T-cells in humans.

Authors:  Andreas Fløe; Caroline Løppke; Ole Hilberg; Christian Wejse; Liselotte Brix; Kivin Jacobsen
Journal:  Immunology       Date:  2017-07-03       Impact factor: 7.397

8.  Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.

Authors:  Winifred Lo; Maria Parkhurst; Paul F Robbins; Eric Tran; Yong-Chen Lu; Li Jia; Jared J Gartner; Anna Pasetto; Drew Deniger; Parisa Malekzadeh; Thomas E Shelton; Todd Prickett; Satyajit Ray; Scott Kivitz; Biman C Paria; Isaac Kriley; David S Schrump; Steven A Rosenberg
Journal:  Cancer Immunol Res       Date:  2019-02-01       Impact factor: 11.151

Review 9.  Neoantigen-based cancer immunotherapy.

Authors:  Sara Bobisse; Periklis G Foukas; George Coukos; Alexandre Harari
Journal:  Ann Transl Med       Date:  2016-07

10.  Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.

Authors:  Rami Yossef; Eric Tran; Drew C Deniger; Alena Gros; Anna Pasetto; Maria R Parkhurst; Jared J Gartner; Todd D Prickett; Gal Cafri; Paul F Robbins; Steven A Rosenberg
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.